BLI:NSD-Berkeley Lights, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 45.54

Change

-0.96 (-2.06)%

Market Cap

USD 3.08B

Volume

1.26M

Average Target Price

USD 95.40 (+109.49%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Berkeley Lights, Inc., a digital cell biology company, focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The company offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software. It serves in North America, the Asia Pacific, and Europe. The company was incorporated in 2011 and is headquartered in Emeryville, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-4.60 (-2.82%)

USD65.51B 109.35 N/A
VRTX Vertex Pharmaceuticals Incorpo..

-2.11 (-0.98%)

USD55.66B 20.49 14.38
REGN Regeneron Pharmaceuticals, Inc

+5.59 (+1.13%)

USD52.92B 16.28 12.68
BNTX BioNTech SE

+18.64 (+10.15%)

USD44.37B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

+1.38 (+0.81%)

USD37.67B 55.32 39.57
BGNE BeiGene, Ltd

-8.65 (-2.77%)

USD28.69B N/A N/A
SGEN Seagen Inc

-3.56 (-2.55%)

USD25.31B 38.92 34.59
RPRX Royalty Pharma plc

+0.52 (+1.27%)

USD24.87B 22.60 14.92
GMAB Genmab A/S

-0.16 (-0.43%)

USD24.33B 26.59 3.07
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BLI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -49.07% 6% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.07% 6% F 3% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 3.08B 88% B+ 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 89% B+ 98% A+
Price/Book Ratio 12.59 16% F 13% F
Price / Cash Flow Ratio -85.96 96% A 94% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -25.31% 79% C+ 33% F
Return on Invested Capital -22.03% 76% C 27% F
Return on Assets -11.72% 81% B- 27% F
Debt to Equity Ratio 3.39% 69% D+ 83% B
Technical Ratios  
Short Ratio 1.51 74% C 65% D
Short Percent 3.04% 80% B- 53% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector